Revance Therapeutics’ (RVNC) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Monday morning, Benzinga reports.

Other analysts have also issued reports about the company. Stifel Nicolaus dropped their price target on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 9th. HC Wainwright downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 13th. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Piper Sandler cut shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Finally, William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $10.29.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $5.90 on Monday. The company has a fifty day moving average price of $5.85 and a 200-day moving average price of $4.30. The firm has a market cap of $618.44 million, a price-to-earnings ratio of -1.86 and a beta of 0.98. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to the consensus estimate of $66.30 million. During the same period in the previous year, the company posted ($0.80) earnings per share. The company’s revenue for the quarter was up 20.2% on a year-over-year basis. On average, research analysts anticipate that Revance Therapeutics will post -1.53 EPS for the current fiscal year.

Institutional Trading of Revance Therapeutics

Institutional investors have recently modified their holdings of the business. Capital World Investors raised its holdings in Revance Therapeutics by 16.8% during the 1st quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock valued at $68,612,000 after acquiring an additional 2,006,459 shares during the period. Stonepine Capital Management LLC lifted its holdings in Revance Therapeutics by 41.7% during the 2nd quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock worth $7,196,000 after purchasing an additional 823,658 shares in the last quarter. Opaleye Management Inc. bought a new position in Revance Therapeutics in the 1st quarter worth about $3,862,000. Federated Hermes Inc. grew its holdings in Revance Therapeutics by 43.0% during the 2nd quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock valued at $5,750,000 after buying an additional 672,803 shares in the last quarter. Finally, Integral Health Asset Management LLC purchased a new stake in shares of Revance Therapeutics in the second quarter worth about $1,285,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.